Olivier David

Title: Olivier David: Innovator in S1P Receptor Modulation

Introduction

Olivier David is a notable inventor based in Mulhouse, France. He has made significant contributions to the field of medicine, particularly in the treatment of multiple sclerosis and other inflammatory disorders. With a total of 2 patents, his work focuses on innovative dosage regimens for S1P receptor modulators.

Latest Patents

David's latest patents include a dosage regimen of an S1P receptor modulator aimed at treating patients suffering from multiple sclerosis. This invention emphasizes the importance of testing patients for a history of infection caused by the varicella zoster virus and ensuring they are vaccinated prior to the administration of the S1P receptor modulator or agonist. Another patent also addresses a dosage regimen for patients with inflammatory or autoimmune disorders, specifically detailing the administration of fingolimod or its pharmaceutically acceptable salts at a daily dosage of 0.5 mg.

Career Highlights

Throughout his career, Olivier David has worked with prominent companies, including Novartis AG. His expertise in the pharmaceutical industry has allowed him to develop innovative solutions that enhance patient care and treatment efficacy.

Collaborations

David has collaborated with notable professionals in his field, including Craig Boulton and Pascale Burtin. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Olivier David's contributions to the field of S1P receptor modulation demonstrate his commitment to improving treatment options for patients with multiple sclerosis and other autoimmune disorders. His innovative patents and collaborations highlight his role as a significant inventor in the medical field.